Interim Data Support Long-term Safety of Orladeyo for HAE Attacks

Interim Data Support Long-term Safety of Orladeyo for HAE Attacks

299041

Interim Data Support Long-term Safety of Orladeyo for HAE Attacks

Treatment with Orladeyo (berotralstat) was generally safe and well-tolerated in people with hereditary angioedema (HAE), according to recently released trial data. The findings from an interim analysis of the open-label APeX-S trial also supported Orladeyo’s ability to reduce the frequency of HAE attacks, ease symptom burden, and improve patients’ quality of life, in line with those of previous studies. The data were reported in a study, “Long-term safety and effectiveness of berotralstat for hereditary angioedema:…

You must be logged in to read/download the full post.